Antibody Formation in Transfusion Therapy

1. Performed to see whether IgG or complement proteins are attached to RBC's in the patient's circulation.
5. An antigen factor that influences antibody production.
6. The class of antibodies involved in transfusion-related anaphylaxis.
7. Typically circulates for approximately 120 days in the human body.
8. Using leukocyte reduced products ____ the risk of alloimmunization.
9. Recent evidence shows that damage to endothelial cells may contribute to the pathology of many diseases such as ____ .
15. Tissue that may be transplanted without the risk of humoral rejection.
16. The pattern recognition sensors within tissues.
17. A final check testing the patient's plasma against donor RBC's in the laboratory to verify that no lysis or agglutination occurs.
18. An anti-CD20 immunosuppressive therapy that binds with the CD20 protein on B cells and inhibits antibody production.
19. May also adhere to cells and generate adaptive immune responses.

2. May occur minutes to hours after the transfusion begins and involves pain, fever, chills, hemoglobinuria, and new or increased bleeding due to disseminated intravascular coagulation.
3. A condition associated with hemolysis, which leads to chronic endothelial inflammation, which then increases the risk of alloimmunization when these patients receive RBC or platelet transfusions.
4. Septic pathogen invasions and endogenous tissue inflammation.
10. Antibodies selected for their specificity to one antigen that also binds to similarly shaped antigens on unintended targets (healthy cells).
11. A strategy used to prevent transfusion-related alloimmunization.
12. The body's largest defense mechanism.
13. A type of lymphocyte that matures into plasma cells, which then produce antibodies.
14. Protection from a disease provided by antibodies created outside of the body.
20. The hallmark of adaptive immunity is the production of ____.